What is Inhibikase Therapeutics, Inc. Common Stock's Market Cap?

Inhibikase Therapeutics, Inc. Common Stock's Market Cap is $336.3M, based on as-reported figures from SEC (XBRL) filings.

What is Inhibikase Therapeutics, Inc. Common Stock's Enterprise Value?

Inhibikase Therapeutics, Inc. Common Stock's Enterprise Value is $177.3M, based on as-reported figures from SEC (XBRL) filings.

What is Inhibikase Therapeutics, Inc. Common Stock's EV / EBITDA?

Inhibikase Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.

What is Inhibikase Therapeutics, Inc. Common Stock's Net Income (TTM)?

Inhibikase Therapeutics, Inc. Common Stock's Net Income (TTM) is -$60.6M, based on as-reported figures from SEC (XBRL) filings.

What is Inhibikase Therapeutics, Inc. Common Stock's EBITDA?

Inhibikase Therapeutics, Inc. Common Stock's EBITDA is -$65.4M, based on as-reported figures from SEC (XBRL) filings.

What is Inhibikase Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?

Inhibikase Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -0.43, based on as-reported figures from SEC (XBRL) filings.

What is Inhibikase Therapeutics, Inc. Common Stock's Net Debt?

Inhibikase Therapeutics, Inc. Common Stock's Net Debt is -$159.0M, based on as-reported figures from SEC (XBRL) filings.

Inhibikase Therapeutics, Inc. Common Stock (IKT) Financial Statements

Inhibikase Therapeutics, Inc. Common Stock

SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

FIGI BBG005TP2348

XNAS · usd

2.41▼ 0.02 (-0.82%)

As of 2026-09-09

Valuation

Market Cap

Enterprise Value

Trailing P/E—

Price / Sales—

EV / Revenue—

EV / EBITDA

Financial Highlights

Revenue (TTM)—

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin—

Net Debt

Trading Information

Previous Close2.43

Day's Range2.38 – 2.45

52-Week Range1.33 – 2.61

Volume323.4K

Avg Volume466.3K

Share Statistics

Shares Outstanding

Employees35

ExchangeXNAS

Listed2020-12-23

Share count as of August 4, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about Inhibikase Therapeutics, Inc. Common Stock (IKT)

What is Inhibikase Therapeutics, Inc. Common Stock's Market Cap?: Inhibikase Therapeutics, Inc. Common Stock's Market Cap is $336.3M, based on as-reported figures from SEC (XBRL) filings.
What is Inhibikase Therapeutics, Inc. Common Stock's Enterprise Value?: Inhibikase Therapeutics, Inc. Common Stock's Enterprise Value is $177.3M, based on as-reported figures from SEC (XBRL) filings.
What is Inhibikase Therapeutics, Inc. Common Stock's EV / EBITDA?: Inhibikase Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Inhibikase Therapeutics, Inc. Common Stock's Net Income (TTM)?: Inhibikase Therapeutics, Inc. Common Stock's Net Income (TTM) is -$60.6M, based on as-reported figures from SEC (XBRL) filings.
What is Inhibikase Therapeutics, Inc. Common Stock's EBITDA?: Inhibikase Therapeutics, Inc. Common Stock's EBITDA is -$65.4M, based on as-reported figures from SEC (XBRL) filings.
What is Inhibikase Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?: Inhibikase Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -0.43, based on as-reported figures from SEC (XBRL) filings.
What is Inhibikase Therapeutics, Inc. Common Stock's Net Debt?: Inhibikase Therapeutics, Inc. Common Stock's Net Debt is -$159.0M, based on as-reported figures from SEC (XBRL) filings.